This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AFMD Affimed (AFMD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Affimed Stock (NASDAQ:AFMD) Get Affimed alerts:Sign Up Key Stats Today's Range$0.18▼$0.1850-Day Range$0.09▼$0.8352-Week Range$0.07▼$1.13VolumeN/AAverage Volume51.16 million shsMarket Capitalization$2.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. Read More Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AFMD Stock News HeadlinesOTC:AFMD.Q (Affimed)May 24, 2025 | fool.caAffimed Stock Price, Quotes and ForecastsMay 17, 2025 | benzinga.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.July 9 at 1:00 AM | Investors Alley (Ad)Cantor Fitzgerald cuts Affimed stock rating on insolvency newsMay 15, 2025 | investing.comAffimed N.V. Files for Insolvency Proceedings Amid Funding ChallengesMay 15, 2025 | nasdaq.comHC Wainwright & Co. Downgrades Affimed N.V. (AFMD)May 15, 2025 | msn.comAffimed N.V.: Affimed Announces Receipt of Nasdaq Delisting NoticeMay 14, 2025 | finanznachrichten.deAffimed (AFMD) Downgraded to Neutral by HC Wainwright & Co. | AFMD Stock NewsMay 14, 2025 | gurufocus.comSee More Headlines AFMD Stock Analysis - Frequently Asked Questions How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) released its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by $0.10. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 193.84% and a negative net margin of 7,836.26%. Read the conference call transcript. When did Affimed's stock split? Affimed shares reverse split before market open on Monday, March 11th 2024.The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Affimed IPO? Affimed (AFMD) raised $96 million in an initial public offering on Friday, September 12th 2014. The company issued 8,000,000 shares at $11.00-$13.00 per share. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Affimed investors own include Meta Platforms (META), NVIDIA (NVDA), Novavax (NVAX), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/10/2021Today7/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AFMD CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees200Year Founded2000Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$114.66 million Net Margins-7,836.26% Pretax Margin-7,837.50% Return on Equity-193.84% Return on Assets-107.24% Debt Debt-to-Equity Ratio0.13 Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual Sales$877 thousand Price / Sales3.33 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book0.04Miscellaneous Outstanding Shares16,100,000Free Float15,488,000Market Cap$2.92 million OptionableNo Data Beta2.07 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AFMD) was last updated on 7/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AFMD Stock Alerts